New partnership injects AI into portable cardiac imaging

Terason, a portable ultrasound manufacturer based in Massachusetts, is partnering with DiA Imaging Analysis, which is headquartered in Israel, to bring AI to healthcare providers using Terason machines for heart imaging.

The collaboration will leverage DiA’s cardiac AI product, LVivo Toolbox, which uses pattern recognition, machine learning and deep learning to increase objectivity in physicians’ interpretations of echocardiograms, according to an announcement.

Suspected trouble with the left ventricle is the most common reason “echoes” are ordered, according to Alice Chiang, PhD, Terason’s CEO and founder.

She notes these exams are crucial for treating as well as diagnosing patients, yet reducing subjectivity in image analysis has historically been a challenge.

Along with cardiology, Terason’s product line includes ultrasound devices for vascular surgery, interventional radiology and other specialties. The company says it was first to turn a laptop into an ultrasound machine.

DiA’s AI technology is designed for use in both acquiring and interpreting ultrasound images.

Hila Goldman-Aslan, DiA’s co-founder and CEO, says the market for point-of-care ultrasound, aka POCUS, is evolving quickly and AI is driving the growth.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.